ArticleOrphanet journal of rare diseases2026
The impact of vision impairment on living with congenital aniridia: a pan-European survey study.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCongenital aniridia is a rare but severe eye disease stemming from genetic variants in PAX6 or related genes and affecting all eye structures, causing lifelong disability. Awareness of the disease is poor even among ophthalmology professionals, and how the ocular pathology impacts quality of life for patients is largely unknown. To improve healthcare for this group, a patient perspective is needed. It was therefore the aim of this study to survey subjects with congenital aniridia from across Europe to determine the impact of vision impairment on their daily lives.
methodsA purpose-developed survey instrument was created and validated by multiple stakeholders and subsequently distributed to individuals and families with congenital aniridia across 15 European countries through European and national aniridia patient associations and the treating ophthalmologists. Survey responses were collected using an online application available in 13 languages or from printed copies. Responses were translated into English and compiled for descriptive and quantitative statistical comparisons.
resultsOf 295 survey respondents (age range 0-79, 58.3% female), photophobia was the most prevalent symptom experienced daily by 83%, followed by 42% experiencing daily dryness, 34% reporting unstable vision daily and 20% experiencing daily ocular pain. 51% of those aged 19 years or younger experienced ocular pain once or more per week, increasing to 61% in adults aged 20 years or older. 93% used a smartphone, of which 55% did not require specialized assistive technology for its use. Most respondents had difficulty recognizing faces, could not read facial expressions, experienced difficulties at school or in the workplace and in social settings, reporting bullying, misunderstandings, social exclusion and isolation. 59% required help at home and 64% outside the home to accomplish daily living tasks, with children requiring help more frequently than adults.
conclusionsCongenital aniridia is characterized by multiple ocular symptoms experienced frequently, affecting daily living in all age groups. Areas to be addressed include provision of adequate symptom relief and improving inclusion, independence, and quality of life for this rare patient group, particularly for children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.